AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD
11.91
-0.80 (-6.29%)
At close: Dec 5, 2022 4:00 PM
12.00
+0.09 (0.76%)
After-hours: Dec 5, 2022 6:30 PM EST
-6.29%
Market Cap 3.64B
Revenue (ttm) 603.19M
Net Income (ttm) 248.36M
Shares Out 285.32M
EPS (ttm) 0.78
PE Ratio 15.27
Forward PE 27.47
Dividend n/a
Ex-Dividend Date n/a
Volume 5,552,344
Open 12.65
Previous Close 12.71
Day's Range 11.85 - 12.72
52-Week Range 5.42 - 15.9
Beta n/a
Analysts Buy
Price Target 29.92 (+151.2%)
Earnings Date Nov 8, 2022

About ABCL

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquart... [Read more]

Industry Biotechnology
IPO Date Dec 11, 2020
Employees 475
Stock Exchange NASDAQ
Ticker Symbol ABCL
Full Company Profile

Financial Performance

In 2021, ABCL's revenue was $375.20 million, an increase of 60.92% compared to the previous year's $233.16 million. Earnings were $153.46 million, an increase of 29.05%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is 29.92, which is an increase of 151.22% from the latest price.

Price Target
$29.92
(151.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Thera...

VANCOUVER, British Columbia & NEW HAVEN, Conn.--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to di...

Other symbols: RLYB
4 days ago - Business Wire

AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

3 weeks ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

3 weeks ago - Zacks Investment Research

AbCellera Reports Q3 2022 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2022 Business Results

3 weeks ago - Business Wire

AbCellera to Present at Upcoming Investor Conferences in November

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November

1 month ago - Business Wire

AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances into Late-Stage Preclinical Development

1 month ago - Business Wire

AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade

The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

1 month ago - Zacks Investment Research

AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

1 month ago - Business Wire

AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

2 months ago - Business Wire

AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines f...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic

2 months ago - Business Wire

Why AbCellera Biologics Rallied as Much as 24% on Wednesday

The contract drug developer's stock is finally shaking off the froth of its initial public offering.

3 months ago - The Motley Fool

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

VANCOUVER, British Columbia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ABCL--AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

4 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

VANCOUVER, British Columbia & SAN FRANCISCO--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for mu...

4 months ago - Business Wire

AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

4 months ago - Business Wire

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S...

5 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?

AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

5 months ago - Zacks Investment Research

Why AbCellera Biologics Is 10% Lower Today

The company has a plan for life after COVID-19, though it pales in comparison.

6 months ago - The Motley Fool

AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

AbCellera Reports Q1 2022 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2022 Business Results

6 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration

7 months ago - Business Wire

AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022

7 months ago - Business Wire